Showing results (131-140 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 1, 1987
Interferon alfa-2b in the treatment of chronic granulocytic leukemiaD E Bergsagel, R H Haas, H A Messner
Investigational New Drugs|September 29, 2020
rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathwayPing Yu, Rui Wu, Zunchun Zhou, et al.
Investigational New Drugs|September 11, 2020
Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cellsDuo Wang, Mengyue Shen, Noriaki Kitamura, et al.
Investigational New Drugs|October 7, 2020
Glochidiol, a natural triterpenoid, exerts its anti-cancer effects by targeting the colchicine binding site of tubulinHongjie Chen, Lijun Miao, Fengxiang Huang, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
Investigational New Drugs|March 12, 2020
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitorsTaihei Ono, Satoshi Igawa, Shintaro Kurahayashi, et al.
Investigational New Drugs|March 14, 2020
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trialSoledad Iseas, Enrique L Roca, Juan M O'Connor, et al.
Investigational New Drugs|January 21, 2020
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growthJungjoong Hwang, Insuk Song, Kwangho Lee, et al.
Investigational New Drugs|March 30, 2020
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteersAndreas Johne, Holger Scheible, Andreas Becker, et al.
Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
Pageof 372